Subscribe

ESMO 2014 - Prostate Cancer

Galeterone is an oral, small-molecule drug that disrupts androgen receptor signaling via multitargeted mechanisms of action, combining androgen receptor degradation and antagonism with cytochrome P17 suppression.
Prognostic models for overall survival (OS) for patients with metastatic castration-resistant prostate cancer (mCRPC) are dated and do not reflect significant advances in treatment options available for these patients
The standard of care for prostate cancer is androgen-deprivation therapy (ADT), and although most patients respond to this treatment, many progress to metastatic castration-resistant prostate cancer (mCRPC).
Abiraterone acetate is a potent inhibitor of cytochrome P450 17 alpha-hydrolase (CYP17A1), causing a decrease in the synthesis of testosterone and a demonstrated overall survival (OS) advantage in patients with metastatic castration-resistant prostate cancer.
The revised guidelines from the National Comprehensive Cancer Network for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) include multiple treatment options, such as the use of sipuleucel-T, an autologous cellular immunotherapy targeting prostatic acid phosphatase, and which is particularly useful for asymptomatic or minimally symptomatic disease.
Androgen receptor splice variant-7 (AR-V7) is a truncated form of the androgen receptor that is the molecular target of enzalutamide and of abiraterone.
Although the majority of patients with metastatic castrate-resistant prostate cancer (mCRPC) respond to androgen-deprivation therapy (ADT), prostate cancer will recur in many patients undergoing ADT.
There is an important unmet need for molecular biomarkers that can predict success or failure of a specific therapy in treating men with metastatic castrate-resistant prostate cancer (mCRPC).
Enzalutamide is approved for the treatment of patients with metastatic castrate-resistant prostate cancer post-docetaxel.
Abiraterone acetate, enzalutamide, and cabazitaxel have been shown to prolong overall survival in patients with metastatic castrate-resistant prostate cancer (mCRPC) who have progressive disease or have become intolerant to docetaxel, but the optimal sequencing of these agents remains unclear.
Page 1 of 2
Results 1 - 10 of 15
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology